慢性心力衰竭和GPX3促进剂甲基化:临床表观遗传学分析
Xufei Zhao1, Li Song1, Xiangwen Li1
1School of Public Health, Shaanxi University of Chinese Medicine, Xianyang 712046, PR China.
Heart & lung : the journal of critical care
|March 5, 2026
概括
在慢性心力衰竭 (CHF) 中,GPX3促进体甲基化模式不同. 特定的CpG位点显示变化的甲基化,可能作为CHF分层和病理生理学的生物标志物.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 心血管疾病研究研究
- 生物标志物发现发现
背景情况:
- 在慢性心力衰竭 (CHF) 中Selenoprotein GPX3的作用是公认的,但其促进体甲基化模式在CHF中需要澄清.
- 了解CHF的表观遗传修饰对于开发新的诊断和治疗策略至关重要.
研究的目的:
- 在患有心血管衰竭的患者中,研究GPX3促进体区域内的CpG甲基化模式.
- 确定GPX3促进体甲基化与CHF患者临床参数之间的关联.
主要方法:
- 在20名CHF患者和20名健康对照中,量化GPX3_FA28促进体区域内的特定CpG位点的甲基化水平.
- 统计分析以比较不同组的甲基化水平.
- 限制立方线 (RCS) 模型的应用,以评估甲基化和临床指标之间的剂量反应关系.
主要成果:
- 与对照组相比,在CHF患者中观察到GPX3促进体的显著位点特异性甲基化变化.
- 确定了CpG_5的高甲基化和CpG_9和CpG_19的低甲基化.
- 在CpG_1和CpG_2的微分甲基化与NYHA类I/II相关.
- 在CpG_5甲基化和包括总 bilirubin,二氧化碳,总胆固醇和血小板数量在内的参数之间发现了非线性关联.
结论:
- 在CHF的背景下,GPX3促进剂甲基化表现出明显的局部特异性.
- 在GPX3促进体内的特定CpG位点可能通过独特的表观遗传机制影响CHF病理生理学.
- GPX3促进剂甲基化作为潜在的CHF分层生物标志物具有前途.
相关概念视频
01:37Epigenetic Regulation
4.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
4.0K
01:46Epigenetic Regulation
34.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.1K
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
588
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
588
01:17Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K